Eduardo Bravo | Chief Executive Officer

Eduardo Bravo, Chief Executive Officer, TiGenix

Mr. Bravo has more than 18 years experience in the pharmaceutical industry. His professional career includes several senior management positions at Sanofi-Aventis, including Vice President for Latin America, where he was in charge of more than 2000 employees and oversaw sales of more than €1 billion. At Sanofi-Aventis he also held positions such as Marketing and Sales Manager for Europe and General Manager for Belgium. He also worked for 7 years in SmithKline Beecham in sales positions both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). Mr. Bravo was a member of the board of Genetrix S.L. from February 2006 until February 2008 and from Biobide S.L. from December 2005 until January 2008. At present, Mr. Bravo is no longer a member of the administrative, management or supervisory bodies or partner of any company or partnership other than TiGenix.


Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 11:40

Panel discussion: Assessment of health technology and market access globally, challenges and pricing

  • How are the logistical challenges for cell and gene therapies going to work in the years ahead?
  • Affordability and sustainability. How are health authorities going to pay?
  • Process of health technology assessment
  • ROI considerations: what makes this product profitable?

back to speakers

World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257